Imlifidase Prior to Kidney Transplant in Highly Sensitised Children

PHASE2RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 2, 2023

Primary Completion Date

February 28, 2027

Study Completion Date

August 31, 2031

Conditions
Kidney Transplantation in Highly Sensitized Patients
Interventions
DRUG

Imlifidase

Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.

Trial Locations (4)

75019

RECRUITING

Robert Debre University Hospital, Paris

00290

RECRUITING

HUS, Helsinki University Hospital, Helsinki

08035

RECRUITING

Hospital Unviersitari Vall d'Hebron, Nefrología Pediátrica, Barcelona

SE-141 86

RECRUITING

Karolinska University Hospital, Huddinge

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Hansa Biopharma AB

INDUSTRY

NCT05753930 - Imlifidase Prior to Kidney Transplant in Highly Sensitised Children | Biotech Hunter | Biotech Hunter